πŸ‡ΊπŸ‡Έ FDA
Patent

US 10085974

Dosage and formulation

granted A61KA61K31/167A61K31/439

Quick answer

US patent 10085974 (Dosage and formulation) held by Almirall, S.A. expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Almirall, S.A.
Grant date
Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/167, A61K31/439, A61K31/46, A61K45/06